Protecting Pharmacies in Medicaid Act
Summary
S927 (Protecting Pharmacies in Medicaid Act) is an early-stage Senate bill that prohibits spread pricing by PBMs in Medicaid. It shifts margin from PBM segments of UNH (Optum Rx) and CI (Express Scripts) to retail pharmacy operators. The bill faces significant hurdles — it has been referred to committee with only 3 cosponsors, no hearings, and no companion House bill. Market impact is minimal at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S927 is an early-stage Senate bill with 3 cosponsors and zero committee activity since introduction in March 2025.
- 2.The bill prohibits spread pricing in Medicaid — this shifts margin from PBMs to retail pharmacies if enacted.
- 3.No companion House bill exists; passage probability in this Congressional session is very low.
- 4.Real market data shows significant recent gains in CVS, UNH, and CI that are unrelated to this bill's prospects.
- 5.Market impact is procedural/near-zero at this stage. Monitor committee markup and House introduction for actionable signals.
Market Implications
S927 has no near-term market impact. The bill is dormant in committee. Real price action over the past 30 days shows CVS at $83.13 (+15.75%), UNH at $364.05 (+34.54%), and CI at $285.83 (+7.15%) — these moves are driven by earnings cycles and sector dynamics, not this stalled legislation. Investors should not make positioning decisions based on S927. Structural watch points: if a companion House bill (H.R. 1768 pathway) advances, or if the Senate Finance Committee schedules a markup, re-evaluate. For now, this is noise.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Prohibition of spread pricing in Medicaid by pharmacy benefit managers, requiring pass-through pricing only.
Who must act
Pharmacy benefit managers operating under Medicaid contracts, including Express Scripts (a division of Cigna).
What happens
Express Scripts must replace spread-based margin with administrative fees or other pass-through revenue for Medicaid drug claims, compressing PBM margin on that book of business.
Stock impact
Express Scripts is one of the three largest PBMs. Medicaid spread pricing is a known profit source; elimination removes a direct margin stream. The impact on $CI is limited because the Medicaid PBM book is a small portion of total Express Scripts claims volume, and Cigna's overall revenue is ~$250B.
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
Veteran Caregiver Reeducation, Reemployment, and Retirement Act
Medicare for All Act
Association Health Plans Act
Protecting Health Care and Lowering Costs Act
Living Donor Protection Act of 2025
Veterans’ ACCESS Act of 2025
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.